Bye bye sleep apnea

Earlier this week, Eli Lilly said that their weight-loss drug Zepbound dramatically improved the symptoms of obstructive sleep apnea according to two late stage trials. This is very good news for the 20 million Americans who suffer from the condition, and for Eli Lilly shareholders.

Doctors will be very likely to prescribe the Zepbound for those with sleep apnea because of the broad benefits in tackling all obesity-related issues. Apparently fat deposits in a person's tongue and upper airway tract are one of the main causes of sleep apnea which is why over-weight people are most likely to suffer from the condition.

There are so many negative side effects of being overweight. I get the sense that we are going to see a lot more conditions that are treatable by Zepbound. Once the FDA gives the green light for these multiple applications, insurers should be more than happy to cover this wonder drug.

The Eli Lilly share price has done well recently for obvious reasons but we believe that the market does not fully appreciate the amount of money that Eli Lilly will make from selling Zepbound in the years ahead. You should add this share to your portfolio.